FDA 21 CFR Part 11 – What Every Business Must Know?
Last Updated on October 29, 2025 by robson nadar Imagine
FDA 21 CFR Part 11 is an important regulation for life sciences, pharma, biotech, and medical device companies. It mainly governs how electronic records and electronic signatures (ERES) are created, stored and managed, making sure there is integrity, security and traceability. Not complying can lead to FDA warning letters, product recalls, legal issues and even reputational damage, all of which may disrupt operations and reduce stakeholder trust.
At VISTA InfoSec, we make FDA 21 CFR Part 11 compliance a bit more simple. Backed with CREST accreditation and decades of industry experience, our team gives clear guidance and practical support to help organizations achieve and also maintain compliance. Whether you’re setting up electronic systems for first time or improving existing ones, we help you align with FDA expectations in an efficient and effective way.
We also provide AuditFusion360, our integrated compliance model which combines Part 11 assessments with other frameworks like ISO 27001, SOC 2, HIPAA and GxP. By bringing overlapping requirements together into one process, AuditFusion360 helps reduce audit fatigue, cut down duplicate controls and gives you one consolidated view of your compliance posture.
Hands-on support to develop or refine SOPs, validation documentation, system configurations, and risk assessments, ensuring both technical and procedural alignment with Part 11.
Comprehensive assessments of your electronic systems, records, and signatures. We review controls, documentation, and validation evidence to confirm compliance readiness and prepare you for FDA inspections.
Full compliance status with detailed findings and gap analysis.
Clear mapping of risks to data integrity and compliance, with recommended mitigations.
A prioritized roadmap to remediate non-compliance and strengthen controls.
Practical recommendations for aligning policies and procedures with FDA standards.
Unified reporting across FDA Part 11 and other frameworks, streamlining compliance oversight.
Staying compliant isn’t a one-time task—it’s an ongoing commitment. We help you stay ahead with:
The purpose of establishing CFR Part 11 is to ensure the authenticity of electronic data and signatures and make them equivalent to paper records and handwritten signatures.
The 21 CFR Part 11 applies to clinical research organizations, pharmaceutical, and medical device companies, who are conducting FDA-regulated research. Any organizations conducting clinical research in the U.S, or submitting their drugs and devices to the FDA for approval, need to comply with CFR Part 11. Every tech or medical device used in clinical research must be compatible with the CFR Part11.
The 21 CFR Part 11 applies to any records that are required by the FDA and are being maintained electronically instead of in a physical format. This includes any electronic document records required by the FDA and mentioned in the Predicate Rule.
The FDA considers electronic signatures equivalent to handwritten signatures but requires the electronic signatures to include the printed name of the signer, date and time of the signature executed, unique user ID, digital adopted signature, and meaning of the signature with labeled signing reason.
Last Updated on October 29, 2025 by robson nadar Imagine
VISTA InfoSec LLC,347 Fifth Ave,
Suite 1402-526, New York, NY 10016
© Copyright 2021. VISTA InfoSec. All Rights Reserved. | Disclosure Policy | Privacy Policy | Sitemap
Enquire Now
WhatsApp us